Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

QLS 32015

Next Previous
Drug Profile

QLS 32015

Alternative Names: QLS-32015

Latest Information Update: 27 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Qilu Pharmaceutical
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Multiple myeloma

Most Recent Events

  • 06 Dec 2025 Efficacy, adverse events and pharmacokinetics data from a phase-Ia/Ib trial in Multiple myeloma presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)
  • 07 Nov 2025 Phase-III clinical trials in Multiple myeloma (Monotherapy, Second-line therapy or greater) in China (SC) (NCT07138209)
  • 15 Sep 2025 Institute of Hematology & Blood Diseases Hospital plans to initiate a early phase I trial for Multiple Myeloma (Second-line therapy or greater, Combination therapy) (Parenteral) (NCT07185477)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top